Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Rejects Apple Trade Secret Theft Claims 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Milei Threatens Falkland Oil Firms With Sanctions 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Add as a preferred source on Google
NEW YORK, March 05, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 30th Annual ROTH Conference on Monday, March 12, 2018 at 9:00 a.m. PT in Orange County, CA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
[email protected]
Source: SELLAS Life Sciences Group, Inc.
